Enzalutamide in Men With High-Risk Biochemically Recurrent Prostate Cancer: Rationale and Treatment Considerations From EMBARK

恩扎卢胺治疗高危生化复发性前列腺癌男性患者:来自 EMBARK 研究的理论依据和治疗考量

阅读:1

Abstract

BACKGROUND: Several genes encoding proteins essential for normal bile production have been associated with progressive familial intrahepatic cholestasis in children, but there are few studies evaluating the frequency of variants in these genes among adults with chronic cholestatic disease. The aim of this study was to assess frequency of variants in progressive familial intrahepatic cholestasis–associated genes in adults with idiopathic or episodic cholestatic chronic liver disease (cCLD). METHODS: Patients with cCLD of unknown cause followed in 4 different reference centers in Brazil were genotyped for ABCB11, ABCB4, ABCC2, ATP8B1, CFTR, JAG1, KIF12, LSR, MYO5B, NR1H4, PPM1F, SERPINA1, TJP2, USP53, VIPAS39, VPS33B, PEX26, and WDR83OS gene variants using Illumina platforms. Primary biliary cholangitis, primary sclerosing cholangitis, and other causes of cCLD were excluded. RESULTS: Sixty-five patients (40 females; mean±SD age at disease onset, 26.8±13.4 y) were included. Most (65%) had either a family history of cholestatic liver disease or previous signs and symptoms of intrahepatic cholestasis of pregnancy or low phospholipid–associated cholelithiasis. Fifty-seven (88%) had cCLD, whereas 8 (12%) reported recurrent episodic cholestasis. Some had evidence at diagnosis of cirrhosis (n=20) or hepatocellular carcinoma (n=2) or had undergone liver transplantation (n=10). Sequencing revealed 28 variants in ABCB4 (n=25) and ABCB11 (n=3) genes in 42 patients [65%; heterozygous (n=31), homozygous (n=4), and compound heterozygous (n=7)]. Only 17 (61%) were previously reported. Most variants (57%) were classified as pathogenic or likely pathogenic. CONCLUSIONS: More than half of the patients with cCLD of unknown cause exhibited pathogenic or likely pathogenic variants in bile transporter genes, particularly ABCB4. Genotyping may identify most of those patients as late-onset patients with multidrug resistance protein 3 deficiency.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。